Introduction
Clinical pregnancy rates associated witb IVF have increased tremendously since the birth of tbe first IVF baby in 1978. Wilh Ihis increase has come a movement to reduce the number of embryos being transferred to avoid high order multiple pregnancies. Effective techniques for cryopreservation of supernumerary embryos for a future cycle are vital to avoid embryo wastage and to augment the pregnancy rate from a single ooeyte retrieval.
Cryopreservation results have been quite variable amongst clinics depending on embryo stage and cryopreservation protocol used. Based on tbe 2004 national registry data for IVF clinics (see US Department of Health and Human Services and the Center for Disease Control and Prevention. 2006) . cryopreservation cycles resulted in a live birtb rate of 28-30% for patients under 38 years of age. Slow freeze protocols using controlled rate freezers that slowly lower tbe temperature to below -3O''C bave traditionally been used forembryo freezing in the clinical laboratory. Different cryoprotectant solutions have been utilized for embryo dehydration depending on cell stage. Propanedioi/sucrose-based protocols have been the most commonly used methodology for slow freezing of pronuclear and early cleavage (2-to 8-cell) stage embryos (Lassalleeffl/. 1985; Testart i-ra/. 1986; Fugger t'/a/. 1988) . Gtyeerol-based cryoprotectant solutions have been favoured for blastocyst cryopreservation (Coben et al., 1985) .
Application of vitrification technology to human embryo eryopreservation has received much attention in reeent years. Vitrification is an ultra-rapid metbod of cryopreservation whereby the embryo is transitioned from 37°C to -I96°C in <l s. High concentrations of cryoprotectants and high cooling rates are necessary to get the embryos into a 'glasslike state' (Vajta and Kuwayama, 2006) . Direct exposure of embryos to liquid nitrogen and Introduction of novel carrier systems that minimize vitrihcation solution volumes have been instrLuncnlal in achieving the rapid temperature shift necessary for this technique to be successful (Park et ai, 2000) .
Human embryo vitrification has been attempted with a variety of vessels such as electron microscope grids (Park et aL. 2000; Son et al.. 2002) . open pulled and hemi-straws (El-Danasouri and Selman. 2001; Vanderzwalmen et al.. 2002 Vanderzwalmen et al.. . 2003 . the flexipipet (Liebermann ci at,. 2002) . the cryotop (Kuyania. 2006) and the cryoloop (Lane et al., 1999; Mukaida ei al,, 2001. 2OO3a.b; Reed et at.. 2002; Rama Raju et at., 2005) .
To date, clinical reports using vitrification have been limited and mainly involve ooeyte (Yoon el al,, 2003; Kuwayama et at.. 200Sb: Kuwayama, 2006) or blastocyst-stage cryopreservation (Hiraoka et al,, 2004; Huang ei at.. 2005; Kuwayama et al.. 2t)05a; Stehlik ei at., 2005; Takahashi et at., 2005; Zech et at., 2005; Kuwayama. 2006; Liebermann and Tucker, 2006) . Cryopreservation of human embryos at the 6-to 8-cell stage using vitrification methodology has not been widely reported (Mukaida ('/a/.. 1998 
etat..2O(i5).
This report presents initial clinical results following vitrification of human embryos on day 3 of culture at the 6-to 8-cell stage. Post-warming embryo morphology and its relationship to pregnancy outcome were assessed. The paper also describes e.xperience with the cryoloop as a carrier for the vitrification procedure.
Materials and methods

Patients
Vitrification was introduced into the authors' clinical practice in November 2002 for cryopreservation of cleavage-stage embryos at the 6-to 8-cell stage, immediately following fresh transfer. Seventy-seven couples undergoing initial IVF treatment between November 2(K)2 and April 2006, relumed for a subsequent warming-cycle. All vitrification-warming cycles were retrospectively analysed. No patient selection or exclusion criteria were used,
Ovarian stimulation
Ovulation induction was carried out after down-regulation with Icuprolide acetate (Lupron; TAP Pharmaceuticals. Lake Forest. lL, USA). FSH (Follistim; Organon. USA or Gonal F; Serono. Italy) was initiated at a dose of 225 lU per day. unless previous stimulations indicated otherwise. When at least two follicles were of 18 mm mean diameter, lO.O(X) IU of human chorionic gonadolrophin (HCG) was administered 36 h before scheduled ooeyte retrieval. Oocytes were recovered by transvaginal aspiration of follicles under ultrasound guidance.
Embryo culture
Patients" oocytes were fertilized by intracytoplasmic sperm injection 3^ h after retrieval. Fertilization check was performed lhe following moming.Zygoles were cultured individually in 20 /(I media drops under an oil overlay. Human lubal lluiil medium (HTF; Life Global. Ontario. Canada) supplemented with 10% synthetic serum substitute (SSS; Irvine Scientific. USA) was used for embryo culture until day 3. All culture was perfomied at 37"C with 5.5% CO, and air. Fresh embryo transfers were performed on day 3. Good quality embryos not selected for transfer were considered for vitrification on day 3 if they were between 6-and 8-cells with <2i.W( fragmentation. Laboratory practice has been to vitrify 2-6 good quality embryos on clay 3 and culture all remaining embryos to the blastocyst stage prior to cryopreservation.
Vitrification procedure
Vitrification of embryos was carried oul by the two-step protocol of Mukaida el al, (2001) . This technique uses dimethylsulphoxide (DMSO). ethylene glyeol and sucrose as lhe cryoprolectant agents. The basal medium was Global Blastocyst Medium (Life Global) with 20% SSS. All steps were performed on a heated laminar (low hood at 37°C. Vitrification Solution #i consisted of 7.5% DMSO and 7.5% ethylene glycol. Following a 2-min incubation, the embryos were moved to Viirificalion Solution #2 containing 15% DMSO, 15% ethylene glycol. 10 mg/ml Ficoll and 0.65 mol/1 sucrose for 35 s. Using a fine micropipette and the aid of a dissecting microscope, the embryos were quickly loaded onto a cryoloop (Hampton Research, Laguna. CA. USA) covered with a thin lilm of the same cryoprotectani (Figure la.b). The cryoloop with embryos was immediately plunged into a vial filled with liquid nitrogen. The liny amouni of fluid used for cryoloop vitrilication (<1 //I) necessitated careful handling of the viirilicd sample lo prevent inadvertent warming during transfer lo and from the large nitrogen storage tank. Each vial was snapped onto a separate cane to facilitate quick transfer of samples. All handling of vials containing viirified embryos was done while keeping the samples immersed in liquid nitrogen or very briefly (<l min) in the vapour phase. Canes were placed in a liquid nitrogen storage tank that was dedicated exclusively lo vitrified embryos.
Warming procedure
Warming of vitrified embryos was also performed al 37''C. The cryoloop was directly immersed in a warming solution containing 0.25 mol/l sucrose. The embryos that fell off the eryoloop were visualized using the dissecting microscope. Following a 2-min rinse, the recovered embryos were moved to the second warming solution, which contained 0.125 mol/1 sucrose. The embryos were incubated for 3 min. The final rinse was in culuire media for 5 min before placement in an incubator at 37''C with 5.5% CO,. The warmed embryos were cultured in Global Blastocyst Medium with 10% SSS until transfer. Cell damage was assessed immediately upon warming. Embryos were considered to be damaged if fewer than half of their blaslomeres were intaci upon warming. The authors' policy has been to transfer all warmed embryos with any sign of vitality regardless of morphology. Only completely degenerated embryos were excluded from transfer.
Embryo replacement
Patients were prepared for vitrified-warmed embryo transfer using hormone replacement therapy consisting of increasing doses of estrace (2-6 mg p.o. daily) and progesterone {50-100 mg i.m.) starting on day 13. The only monitoring in the replacement cycle was the evaluation of endometrium prior to progesterone administration. Warming cycles were cancelled if the endometrial thickness was <7 mm. Vitrified cleavage-stage embryos were warmed and cultured for 48 h before transfer on day 5 of progesterone administration. Postwarming survival and daily development were monitored. All embryos were photographed at three time points: at vitrification, immediately upon warming and just prior to transfer. Embryo transfer was performed under ultrasound guidance using a Wallace Sure View catheter (Irvine Scientific). Pregnancy testing was performed 15 days after the embryo transfer. Clinical pregnancy was confirmed by Ihe presence of a fetal heart beat on ultrasound examination at 6-8 weeks. The implantation rate was derived from the number of fetuses with a heart beat divided by the total number of embryos transferred. Table 1 presents results for human embryos vitrified at lhe 6-to 8-cell stage. The data set represents consecutive vitrification-warming cycles performed over a 2.5-year interval. A total of 236 embryos were warmed. The average number of embryos transferred per patient was 2.66 ± 0.86. All warming cycles resulted in a transfer.
Results
The clinical pregnancy rate was 44% (34/77) and the implantation rate was 20^/r (40/201). The embryos were evaluated for blastomere number and cytoplasmic integrity. The post-warming survival rate was 85% (201 /236). Only 4.5% of surviving embryos had outward signs of injury and considerable hlastomere cell loss on thawing. Figure 2 shows the excellent morphology typically seen following warming of vitrified human embryos.
It was found thai 78% (184/236) of warmed embryos showed signs of embryonic compaction and/or blastulation by the time of transfer. The bUistulation rate from warmed cleavage-stage embryos was 44% after 48 h in culture. Predominantly early stage blastocysts were noted during lhe morning observation but by late afternoon expansion was clearly evident in high quality embryos. The timely post-warming development of vitrified embryos appeared to be an excellent indicator of subsequent developmental potential. Morphology on the day of viirified-warmed embryo transfer was associated with pregnancy outcome. In transfers where at least one warmed embryo reached the blastocyst stage by the day of transfer, the pregnancy rate was 58% (28/48). In contrast, when warmed embryos developed only lo the morula/ compacting stage by ihe transfer day. lhe pregnancy rate was notably lower, at 26% (6/23). No pregnancies occurred when the embryos failed to show signs of compaction by the day of transfer (0/6).
Thirty singleton pregnancies and two sets of twins and triplets were conceived. To date, there have been 11 deliveries of healthy infants and two miscarriages. No congenital anomalies have been reported. 
Discussion
The present series, achieved exclusively with cryoioop vitrification, represents the largest clinical series to date showing successful vitrification of day 3 cleavage-stage embryos.
Vitrification technology has been shown to be a very promising alternative to slow-freezing mcthtxlology for cryopreservation of chill-sensitive cells such as ootytes (Hong et at,. 1999; Chung et at., 2000; Kuleshova and Lopata. 2002; Liebermann et at., 2003; Yoon et al., 2003; Chian et al., 2004; Liebermann and Tucker, 2004; Kuwayama et aL, 2005b; Kuwayama. 2006 ) and even for biastocyst-stage embryos with large fluid volumes (Lane et ai. 1999; Reed et al., 2002; Mukaida et ai. 2003b; Vanderzwalmen et al,, 2003; Liebermann and Tucker. 2004 The present clinical trial, in contrast to the aforementioned studies, used a combination of DMSO and ethylene glycol. It was thus possible to use lower concentrations of individual cryoprotectants. thereby possibly reducing any cytotoxic effects (Kasai et ai. 1992; Zhu et ai. 1993; Archer et ai. 2003) . The current two-step protocol adapted from Mukaida et ai (2001 Mukaida et ai ( . 2002 involved exposing embryos to 7.5% DMSO/ethylene glycol for 2 min followed by 35 s in the final vitrification solution containing 15% DMSO/ethylene giycol. sucrose and Ficoil. This fonnulation was originally developed for biastocyst-stage cryopreservation. and to date there have been no clinical reports on day 3 cleavage-stage embryos using this protocol.
One positive attribute following vitrification-wanning with this protocol was the remarkably low percentage of embryos with considerable cellular damage (4.5%). Historically, with the conventional slow freezing protocol using cryovials. almost a quarter of human embryos surviving the freeze-thaw pr(K:ess had greater than 50% damage, resulting in blastomere toss and degeneration (Desai et aL. 2(X) 3). Higher damage rates with conventional slow freezing compared with vitrification have been observed by others (Walker el ai. 2004) . Cell loss on thawing has also been related to reduced pregnancy rates (Archer ei aL. 2(K)3).
Another advantage of the vitrification procedure was that it was extremely efficient, taking <5 min as compared with the moi-e lengthy programmed slow freezing protixols, which required a minimum of 2 h per run and several freezer units to accommodate cryopreservation for all patients. Introduction of cryoloop vitrification to the clinical laboratory did. however, require extensive technician training with mouse embryos. The embryologist's speed and skill in performing the vitrification-warming procedure were paramount to success.
This series was also unique in that wanned cleavage-stage embryos were cultured until the morula/early blastocyst stage prior to transfer. Culture for this additional 48-h interval allowed better assessment of post-warming damage and embryonic potential after vitrification. This work demonstrates a clear relationship between einbryt>nic compaction after warming and subsequent developmental potential. Lieberman and Tucker (2002) using embryos derived from abnormally fertilized zygotes cultured to day 3. found that only 39% of vitrified-warmed embryos were capabie of compaction. The high compaction rate (78%') observed in the present study was reflective of overall embryo quality on wanning. It also attests to the suitability of this vitrification procedure for human embryo cryopreservation. Vitrification at the cleavage .stage allowed more embryos to be vitrified per patient and idleviated the need for extended culture of large numbers of spare embryos. The patient also benefited by having embryos frozen at both early and late stages.
The pregnancy and implantation rates achieved in this series are indicative of the tremendous potential of vitrification in the ciinicai setting. The ciinicai pregnancy rate of 44%' and the embryo implantation rate of 20% were higher Ihan historical results wilh slow progriuiimed freezing (Desai et ai, 2003) . Introduction of this technology into the laboratory allowed for more efficient cryopreservation of palient embryos with good success rates.
One issue with vitrification on cryoloops is that it involves direct exposure to liquid nitrogen. The risk of cross-contamination in liquid nitrogen storage containers even at -I96"°C has been widely debated (Bicianski el aL. 2000. 2(X)3). This concern was addressed in part by keeping all vitrified embryos in a separate, newly purchased tank. With cryoloops. the voiume of fluid in each vial was iess than 1 /d and at its maximum capacity the liquid nitrogen storage Dewar couki handle 320 vials (one vial per cane). With less ihan 320 //I of fluid in the entire 79 I tank, it vvas felt that the risk of possible cross-contamination was minimal. Other 'closed' systems for vitrification are being considered, but most involve heat-sealing ofthe can'ier vessel. If heal is transfen-ed to a sample, it could have a negative impact, especially with vitrification, since fluid volumes are so small.
In conclusion, initial experiences with vitrification of human embryos were positive. The vitrification prcvedure has been adapted successfully to the authors" IVF laboratory after a |ieri(Kl of employee training, and the clinical pregnancy and implantation rates were promising. Moreover, it was found that the cryoloop was an excellent carrier for ultra-rapid cryopreservation of embryos. This study suppoiis the effectiveness of a DMSO/ethylene glycol cryoprotectant combination for viunfication of human embryos at the 6-to 8-cell stage. Moreover, ethylene glyco! could be used at far iower concentrations than has previously been rt'poiied for cieavage-stage vitrification. Il remains to be determined if this same protocol can be applied to other cell stages with equal success.
